Serono

EMD Serono and FAST FORWARD, LLC Announce Collaboration to Accelerate Development of Treatments for Multiple Sclerosis

-- EMD Serono and Fast Forward agree to work together to speed research development on a select group of high potential MS research projects with support of up to $19 million in funding ROCKLAND, Mass. and NEW YORK, March 18/PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmsta...

Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis

- Merck Serono and Apitope to Collaborate on Development and Commercialization of ATX-MS-1467, Apitope's Peptide Therapeutic for the Treatment of Multiple Sclerosis (MS) GENEVA, Jan. 13 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the signature o...

EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States

-- EMD Serono to acquire US rights in tesamorelin, a Phase III compound being investigated for the treatment of excess abdominal fat in HIV patients with lipodystrophy -- Theratechnologies to receive up to US$215 million plus increasing -- royalties on net sales in the US -- Me...

BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono

NOVATO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has re-acquired the Canadian rights for tetrahydrobiopterin (BH4), including Kuvan(TM) (sapropterin dihydrochloride), from Merck Serono, a division of Merck KGaA, Darms...

Calling All Aspiring Filmmakers! The In The Know Short Film Competition Announces Call for Entries Women and Couples Encouraged to Enter TODAY, Share Their Fertility Stories and Inspire Others

... LifeLines™, a free patient resource provided by EMD Serono, the company that brings you Gonal-f® (follitropin alfa for injection). EMD serono is proud to announce that it will be donating up to $1.5 million in product to patients at fertility centers across the country to help couples strugg...

Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts

... Ltd., Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck serono SA, Novartis AG, sanofi-aventis SA, Schering-Plough Corporation, Shire Pharmaceuticals Group plc., Teva Pharmaceuticals Industries Limited, UCB Pharma...

Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking?

... the National MS Society in collaboration with EMD serono between November 2008 and February 2009. The surve...ng www.nationalMSsociety.org . About EMD serono EMD Serono, Inc., an affiliate of Merck KGaA, D...(TM) (somatropin (rDNA origin) for injection). EMD serono is a leader in fertility treatments, with Gonal-f(...

EMD Serono, Inc. Announces Expansion with Research Site in Cambridge, Massachusetts

...xisting US research in oncology and fertility. EMD serono expects to occupy the site with nearly 50 scientis...n Firouz, President and CEO, EMD Serono, Inc. "EMD serono is following our outlined strategy to broaden our ...at leading biopharmaceutical companies such as EMD serono have stability with hiring, expanding and investin...

Rigel Announces Fourth Quarter and Year End 2008 Financial Results

...ed to $8.0 million reported in the fourth quarter of 2007. Revenue in the fourth quarter of 2007 included a $3.0 million milestone payment from Merck serono for licensing rights in Japan for R763 and a $5.0 million milestone payment from Pfizer for the initiation of its Phase 1 clinical trial for R343. ...

Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference

...1, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Microm...

Serono in Medical Technology

Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance

SAN DIEGO, Feb. 24 /PRNewswire/ -- Ambrx Inc, and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced a global strategic collaboration to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple sclerosis. ARX424 was created by A...

Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis

- ORACLE MS Phase III Trial Will Assess Effectiveness of Cladribine Tablets in Preventing Conversion to Definite Multiple Sclerosis in Addition to the Fully Enrolled Phase III Pivotal Trial - - the CLARITY Study - - for Treatment of Relapsing Forms of...

Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis

GENEVA, Sept. 17 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment has been completed in the REFLEX trial (Rebif FLEXible dosing in early multiple sclerosis). This randomized, double-blind, placebo-controlled, international Phas...

MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders

NEW YORK, Dec. 13 /PRNewswire-USNewswire/ --- The Michael J. Fox Foundation for Parkinson's Research has committed up to $2 million for research toward therapies to alleviate Parkinson's-related cognitive dysfunction and mood disorders. The funding is to be awarded under a new initiative, Cogn...

Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting

GENEVA, Switzerland, April 27, 2007 – Merck Serono S.A. (virt-x: SEO) and its partner Newron Pharmaceuticals S.p.A. (SWX: NWRN) announced today that Professor Fabrizio Stocchi, MD, PhD, will present the results of the first Phase III trial of safinamide as an adjunctive treatment to dopam...

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis

...sive information on this safety aspect. Merck serono plans to submit Cladribine Tablets for registratio...sing forms of multiple sclerosis. About Merck serono and multiple sclerosis Merck serono is a leader in multiple sclerosis (MS) with Rebif(...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

...programs independently and with its partners Bayer Schering, Nycomed, Merck serono and MedImmune." An archive of the event's presentations is available a...lid tumors. Micromet is developing adecatumumab in collaboration with Merck serono in a phase 1b clinical trial evaluating adecatumumab in combination with do...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

...1, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Microm...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

...1, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Microm...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

...1, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Microm...

Serono in Biological News

EMD Serono launches easypod, new electronic growth hormone injection device

Rockland, Massachusetts, December 6, 2007 - EMD Serono, Inc. announced today the availability of easypod, the first of its kind automated device in the growth hormone therapeutic area. easypod was developed for the administration of Saizen [somatropin (rDNA origin) for injection], the companys tr...

Self-digestion as a means of survival

... membrane. Here, the protein waste can dock onto the autophagosome and can then be wrapped up in the membrane. Vladimir Kirkin, who is now at Merck serono in Darmstadt, is continuing these investigations with the long-term aim of developing new drugs. Dikic and his group are now concentrating on mitochon...

Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer

...mitochondrial membrane was responsible for chemotherapy resistance. In collaboration with the University of the Basque Country and the Swiss firm Merk serono International, a model in liposomes simulating the composition of the mitochondrial membrane was developed in order to check the effects of cholestero...

Serono in Biological Technology

Merck Serono Launches Strategic Venture Capital Fund

- New Venture Capital Fund Will Invest in Biotech Start-up Companies Focused on Merck Serono's Core Therapeutic Areas GENEVA, March 23 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the formation of 'Merck Serono Ventures', a strategic, cor...

EMD Serono Launches Landmark Patient Registry for Egg Freezing

The HOPE Registry is an observational study undertaken to evaluate the safety and efficacy of oocyte cryopreservation (egg freezing) techniques ROCKLAND, Mass., Nov. 7 /PRNewswire/-- EMD Serono, Inc., an affiliate of Merck KGaA of Darmstadt, Germany, announced the launch of the Human Oocyte...

Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease

- Five research teams selected to receive funding for preclinical and clinical research projects in Parkinson's disease-related cognitive deficits and mood disorders ROCKLAND, Mass., Oct. 14 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) aw...

Merck Serono Named as a Top Employer by Science Magazine

GENEVA, Switzerland, October 10 /PRNewswire-FirstCall/ -- - Ranked Number 7 out of top 20 Employers Across Life Sciences Industry Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has been named by Science magazine as a top employer in the biotechnology an...

EMD Serono Named as a Top Employer by Science Magazine

- Ranked Number 7 out of top 20 Employers Across Life Sciences Industry - ROCKLAND, Mass., Oct. 9 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it has been named by Science magazine as a top employer in the biotechnology and pharmaceutica...

EMD Serono to Adopt Revised and Strengthened PhRMA Code

- Revised Code Demonstrates Strong Commitment to Ethical Information Exchange between Physician Community and Leading Biotechnology and Pharmaceutical Companies - ROCKLAND, Mass., July 10 /PRNewswire/ -- EMD Serono, Inc. announced today that the company has adopted an...

EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts

ROCKLAND, Mass., April 16 /PRNewswire/ -- Merck Serono and its US affiliate EMD Serono, Inc., both part of Merck KGaA, Darmstadt, Germany, announced today a planned expansion of EMD Serono's US presence with an anticipated investment of $50 million at its Billerica facility northwest of Boston...

Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device

Award-winning device designed for patient ease of use, reliability and convenience ROCKLAND, Mass., Dec. 6 /PRNewswire-FirstCall/ -- EMD Serono, Inc. announced today the availability of easypod(R), the first of its kind automated device in the growth hormone thera...

ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis

- Patient enrollment to begin in fourth quarter - SEATTLE, Oct. 4 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (Nasdaq: ZGEN) today announced that, together with its collaborator Merck Serono, it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Pro...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

...ion programs (controlled ovulation stimulation/assisted reproductive technologies) in Europe, the USA and Japan. It was launched on the market through serono (now Merck Serono) in the U.S., Europe and in several other countries, as well as in Japan through Shionogi. About Benign Prostatic Hyperplasia ...

Serono in Biological Definition

Biotechnology

...enome Project Biotechnology firms The top 10 publicly-traded biotechnology companies, ranked by 2003 sales, are: Amgen Genentech serono Biogen Idec Chiron Genzyme MedImmune Gilead Sciences Cephalon Millennium Pharmaceuticals Biotechnology in fiction ...